BIRC2 and ovarian cancer: We previously established that COL11A1 promotes cisplatin resistance in ovarian cancer cells through activation of NFkB and upregulation of specific inhibitors of apoptosis (IAPs; BIRC2, BIRC3, and XIAP) [9].